Sequenom, the San Diego-based developer of a non-invasive prenatal test for Down Syndrome, said today it has acquired Ann Arbor, MI-based SensiGen for $8.7 million, plus potential milestones. The deal gives Sequenom (NASDAQ: [[ticker:SQNM]]) molecular diagnostics for human papillomavirus, lupus, chronic kidney disease, and inflammatory bowel disease. The purchase is part of Sequenom’s strategy to offer diagnostics for women’s health and cancer, CEO Harry Stylli said in a statement.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
